Mentions
Extended reach
Total likes
Video views
AI synopsis
The discussions reveal a strong interest in the research, with comments highlighting the effectiveness of bempedoic acid in reducing cardiovascular events for statin-intolerant patients. Phrases like 'compared to placebo' and 'significantly reduced major adverse cardiovascular events' indicate an analytical approach and concern for practical implications. Additionally, tone variations, from enthusiastic endorsements to cautious considerations of possible side effects, illustrate the community’s deeper engagement with the article, driving multifaceted conversations around its conclusions.
The majority of discussions express a positive outlook on bempedoic acid's effectiveness, indicating general support for the article's findings.
Participants display a high level of curiosity about the implications of the study, often asking questions or sharing insights to deepen understanding.
While some posts explore the methodology, others focus on specific outcomes, showing moderate depth in engagement with the content.
Many contributors believe that the findings of the article could significantly influence treatment options for statin-intolerant patients.
This week’s most cited articles: 1. Bempedoic Acid and Cardiovascular Outcomes in Statin-Intolerant Patients https://t.co/V3FTTsOLd1 #cardiology https://t.co/ArVJZVd3pN
#ACC / #NEJM 同時発表の論文二つ目は、スタチンが飲めないCVDハイリスク患者に朗報。 HMG-CoAのさらに上流を阻害してLDLを低下させるというベンペド酸が、主要心血管イベント発生を抑制しました。 https://t.co/wHDoFSqVqD ・2020年の大塚製薬リリースはこちら↓ https://t.co/wmyKotU8LU https://t.co/0ehMr4LZZl
Kind reminder to analyse a RCT on #LLT : consider baseline hashtag#CVR, magnitude of #LDL decrease and #TimeExposure to #LLT https://t.co/GAH1XfUPDP
Can't take #statins? New pill cuts #cholesterol, heart attacks @nejm https://t.co/je56rXLAhn https://t.co/mb6px7czNf
12/ If a shared decision to re-trial a lower dose statin is unsuccessful, you would next reach for ezetimibe or a PCSK-9 inhibitor. After that, you may consider bempedoic acid. https://t.co/Mwg9jUFPV5 https://t.co/ANIt0n2ETD
This week’s most cited article: Bempedoic Acid and Cardiovascular Outcomes in Statin-Intolerant Patients https://t.co/2GIT1lJ5rJ #ClinicalMedicine https://t.co/OVcfXfZGNY
In this video, Dr. Sten Ekberg's cholesterol claims are critically analyzed against scientific evidence. Bempedoic acid, an ATP citrate lyase inhibitor, effectively reduces LDL cholesterol with fewer side effects…
This video explores the impact of climate change on marine ecosystems. It highlights key research findings on ocean temperature rise, acidification, and their effects on biodiversity. Discover how these changes threaten…
Bempedoic acid is now available in pharmacies as a therapeutic alternative for patients with dyslipidemia who cannot tolerate statins. This video discusses its clinical trial results, showing significant reductions in…
https://t.co/Ef4yivMOBw
RT @SantasEnrique: CLEAR Outcomes #ACC23 @NEJM ✅ En pacientes con intolerancia a estatinas el ácido bempedoico redujo los eventos CV ✅…
RT @cardiomet_CE: 11) #Bempedoic acid is a new oral non-statin agent that has cardiovascular outcome data supporting its use from the #CLEA…
11) #Bempedoic acid is a new oral non-statin agent that has cardiovascular outcome data supporting its use from the #CLEAR_OUTCOMES trial. Particularly in statin-intolerant patients, this seems to be a useful strategy. See https://t.co/USdISGoEZO https://t.co/HU2a1Ewayt
@cremieuxrecueil Also bempadoic acid (which also comes in a combo Ezitimbe pill). https://t.co/gqBssD3srZ
@Medscape “Inflammation leads to plaque buildup, atherosclerosis and coronary artery disease.” @DrJimLiu, N. Jones & E. Spatz via @Medscape BEMPEDOIC ACID ⬇️ hs-CRP 2️⃣1️⃣% in the
RT @SABOURETCardio: Kind reminder to analyse a RCT on #LLT : consider baseline hashtag#CVR, magnitude of #LDL decrease and #TimeExposure to…
RT @SABOURETCardio: Kind reminder to analyse a RCT on #LLT : consider baseline hashtag#CVR, magnitude of #LDL decrease and #TimeExposure to…
RT @SABOURETCardio: Kind reminder to analyse a RCT on #LLT : consider baseline hashtag#CVR, magnitude of #LDL decrease and #TimeExposure to…
RT @SABOURETCardio: Kind reminder to analyse a RCT on #LLT : consider baseline hashtag#CVR, magnitude of #LDL decrease and #TimeExposure to…
RT @SABOURETCardio: Kind reminder to analyse a RCT on #LLT : consider baseline hashtag#CVR, magnitude of #LDL decrease and #TimeExposure to…
RT @SABOURETCardio: Kind reminder to analyse a RCT on #LLT : consider baseline hashtag#CVR, magnitude of #LDL decrease and #TimeExposure to…
RT @SABOURETCardio: Kind reminder to analyse a RCT on #LLT : consider baseline hashtag#CVR, magnitude of #LDL decrease and #TimeExposure to…
Kind reminder to analyse a RCT on #LLT : consider baseline hashtag#CVR, magnitude of #LDL decrease and #TimeExposure to #LLT https://t.co/GAH1XfUPDP
@OdaQ_DM いや、私も去年この論文見て日本で発売されないのかなー内服だし、PCSK9よりは安いだろうしーと思ってたくらいでした
How ‘bout those RCTs? “Bempedoic acid had no significant effects on fatal or nonfatal stroke, death from cardiovascular causes, and death from any cause. The incidences of gout and cholelithiasis were higher with bempedoic acid than with placebo” Oh. DOI 10.1056/NEJMoa2215024 https://t.co/ie3VpxmapH
@shannonrwatts Bempedoic acid is a sufficient cholesterol reducer, can be combined with ezetemibe https://t.co/D3MnniKZFf
RT @LuckasSalomon: Bempedoic Acid and Cardiovascular Outcomes in Statin-Intolerant Patients https://t.co/oJOq7F8YZW
Mas info: https://t.co/kEto5NVgNL https://t.co/C692vKuTkZ https://t.co/9ACQG232hT https://t.co/6sCZDVDMxk https://t.co/TEV8v6lao9
Bempedoic Acid and Cardiovascular Outcomes in Statin-Intolerant Patients https://t.co/oJOq7F8YZW
RT @DrDerekConnolly: @doctorsaluja @Garyr9912 @EUdaiichisankyo @PeterAttiaMD @MohammedAlo @payalkohlimd @drpablocorral @ProfKausikRay It’s…
@doctorsaluja @Garyr9912 @EUdaiichisankyo @PeterAttiaMD @MohammedAlo @payalkohlimd @drpablocorral @ProfKausikRay It’s the perfect lipid lowering therapy for patients who made the entry criteria for Clear Outcomes and in England as per NICE guidance I prescribe it every day so it is mainstream
RT @Garyr9912: @shivadas29 @Griffith17431 @KenDBerryMD @MohammedAlo @PeterAttiaMD Here’s the big publishing on the trial. https://t.co/0U…
@shivadas29 @Griffith17431 @KenDBerryMD @MohammedAlo @PeterAttiaMD Here’s the big publishing on the trial. https://t.co/0U6IPxQXim
6) One of these new non-statin therapies is #bempedoic_acid, approved by @US_FDA in 2022. The #CLEAR Outcomes trial showing #cardiovascular benefit was published in @nejm: https://t.co/OG2ntak2Ce https://t.co/cbI6ic6kbr
RT @Fmhub_org: #يحدث_الآن ⚡️Join us in exploring the article exploring the efficacy of Bempedoic acid in reducing major adverse cardiovas…
RT @manopsi: New England ตีพิมพ์ RCT ของ bempedoic acid ยาลด cholesterol ตัวใหม่ที่ยับยั้ง ATP citrate lyase ในกระบวนการก่อนเปลี่ยน HMG-CoA…
RT @javier20ch: Ácido bempedoico y MACE en
RT @Fmhub_org: #يحدث_الآن ⚡️Join us in exploring the article exploring the efficacy of Bempedoic acid in reducing major adverse cardiovas…
#يحدث_الآن ⚡️Join us in exploring the article exploring the efficacy of Bempedoic acid in reducing major adverse cardiovascular events in statin- intolerant patients✨
@SocietyGIM Source Article: Nissen SE, Lincoff AM, Brennan D, etal. Bem-pedoic Acid and Cardiovascular Outcomes in Statin-Intolerant Patients. N Engl J Med. 2023;388(15):1353-1364. https://t.co/Hgd2IuHSjz
RT @chemachir:
RT @chemachir:
RT @chemachir:
RT @chemachir:
RT @chemachir:
RT @chemachir:
@theproof Why none of the FDA approved statins never showed to reduce mortality. Latest case of Bempedoic acid which showed a higher mortality in Phase 3 than placebo. But it reduce the famous biomarker called LDL. See table 2 https://t.co/z7nxWygs8Y
RT @cardiomet_CE: 4b) Primary manuscript at
RT @cardiomet_CE: 4b) Primary manuscript at
4b) Primary manuscript at
Interesting study on bempedoic acid and it’s CV effects! #TwitteRx https://t.co/Zgq1CK7yBw
@jl35wilsonMD @DavidLBrownMD CLEAR OUTCOMES is all I know Agreed-- havent gotten it covered yet https://t.co/onG98MurD4
RT @FtNegar:
RT @javier20ch: Ácido bempedoico y MACE en
Any other statin intolerance meds https://t.co/fUwGBZfdyL https://t.co/WenlsIUPrZ
@HighWireTalk https://t.co/CkDwvV0dvo
Full article open access #FOAMed : https://t.co/Xevsj7PV7u
Bempedoic Acid and Cardiovascular Outcomes in Statin-Intolerant Patients | NEJM https://t.co/zIdz7SaMAX
10b) You recall those data--and you can still earn
【備忘】 JCL誌に、スタチン不忍容例を対象としたPCT “CLEAR Outcomes” [https://t.co/inS572LB7N] の有害事象詳細。 胆石症は ベンペド酸群 2.2% [0.6/100人年]、プラセボ群 1.2% [検定不詳] 。腎障害や２DM発症、筋痛、腱障害発生率には大差なし。 https://t.co/zzSD3i7HGs https://t.co/lvycAB40hh
https://t.co/tkXkI0tzwz
RT @ezeforte:
https://t.co/5uFBWdjLmO
@ketogrillbakery @DanClintonRN @EsperionInc @EUdaiichisankyo Certainly don’t listen to me or a nurse, read up on it. Over 14,000 patients over 4 yrs, New England Journal of Medicine, professors, cardiologists, and doctors around the world were very impressed with these results. Look at the heart attacks&stenting
https://t.co/Xevsj7PV7u
RT @NEJM: This week’s most cited article: Bempedoic Acid and Cardiovascular Outcomes in Statin-Intolerant Patients https://t.co/2GIT1lJ5rJ…
RT @NEJM: This week’s most cited article: Bempedoic Acid and Cardiovascular Outcomes in Statin-Intolerant Patients https://t.co/2GIT1lJ5rJ…
RT @NEJM: This week’s most cited article: Bempedoic Acid and Cardiovascular Outcomes in Statin-Intolerant Patients https://t.co/2GIT1lJ5rJ…
RT @NEJM: This week’s most cited article: Bempedoic Acid and Cardiovascular Outcomes in Statin-Intolerant Patients https://t.co/2GIT1lJ5rJ…
RT @NEJM: This week’s most cited article: Bempedoic Acid and Cardiovascular Outcomes in Statin-Intolerant Patients https://t.co/2GIT1lJ5rJ…
RT @NEJM: This week’s most cited article: Bempedoic Acid and Cardiovascular Outcomes in Statin-Intolerant Patients https://t.co/2GIT1lJ5rJ…
Bempedoic Acid and Cardiovascular Outcomes in Statin-Intolerant Patients | NEJM https://t.co/7nV5svlIu6
This week’s most cited article: Bempedoic Acid and Cardiovascular Outcomes in Statin-Intolerant Patients https://t.co/2GIT1lJ5rJ #ClinicalMedicine https://t.co/OVcfXfZGNY
RT @NEJM: This week’s most cited articles: 1. Bempedoic Acid and Cardiovascular Outcomes in Statin-Intolerant Patients https://t.co/V3FTT…
RT @NEJM: This week’s most cited articles: 1. Bempedoic Acid and Cardiovascular Outcomes in Statin-Intolerant Patients https://t.co/V3FTT…
RT @NEJM: This week’s most cited articles: 1. Bempedoic Acid and Cardiovascular Outcomes in Statin-Intolerant Patients https://t.co/V3FTT…
RT @NEJM: This week’s most cited articles: 1. Bempedoic Acid and Cardiovascular Outcomes in Statin-Intolerant Patients https://t.co/V3FTT…
RT @NEJM: This week’s most cited articles: 1. Bempedoic Acid and Cardiovascular Outcomes in Statin-Intolerant Patients https://t.co/V3FTT…
RT @NEJM: This week’s most cited articles: 1. Bempedoic Acid and Cardiovascular Outcomes in Statin-Intolerant Patients https://t.co/V3FTT…
RT @NEJM: This week’s most cited articles: 1. Bempedoic Acid and Cardiovascular Outcomes in Statin-Intolerant Patients https://t.co/V3FTT…
RT @NEJM: This week’s most cited articles: 1. Bempedoic Acid and Cardiovascular Outcomes in Statin-Intolerant Patients https://t.co/V3FTT…
RT @NEJM: This week’s most cited articles: 1. Bempedoic Acid and Cardiovascular Outcomes in Statin-Intolerant Patients https://t.co/V3FTT…
RT @NEJM: This week’s most cited articles: 1. Bempedoic Acid and Cardiovascular Outcomes in Statin-Intolerant Patients https://t.co/V3FTT…
RT @NEJM: This week’s most cited articles: 1. Bempedoic Acid and Cardiovascular Outcomes in Statin-Intolerant Patients https://t.co/V3FTT…
RT @NEJM: This week’s most cited articles: 1. Bempedoic Acid and Cardiovascular Outcomes in Statin-Intolerant Patients https://t.co/V3FTT…
RT @NEJM: This week’s most cited articles: 1. Bempedoic Acid and Cardiovascular Outcomes in Statin-Intolerant Patients https://t.co/V3FTT…
RT @NEJM: This week’s most cited articles: 1. Bempedoic Acid and Cardiovascular Outcomes in Statin-Intolerant Patients https://t.co/V3FTT…
RT @NEJM: This week’s most cited articles: 1. Bempedoic Acid and Cardiovascular Outcomes in Statin-Intolerant Patients https://t.co/V3FTT…
RT @NEJM: This week’s most cited articles: 1. Bempedoic Acid and Cardiovascular Outcomes in Statin-Intolerant Patients https://t.co/V3FTT…
RT @NEJM: This week’s most cited articles: 1. Bempedoic Acid and Cardiovascular Outcomes in Statin-Intolerant Patients https://t.co/V3FTT…
RT @NEJM: This week’s most cited articles: 1. Bempedoic Acid and Cardiovascular Outcomes in Statin-Intolerant Patients https://t.co/V3FTT…
RT @NEJM: This week’s most cited articles: 1. Bempedoic Acid and Cardiovascular Outcomes in Statin-Intolerant Patients https://t.co/V3FTT…
RT @NEJM: This week’s most cited articles: 1. Bempedoic Acid and Cardiovascular Outcomes in Statin-Intolerant Patients https://t.co/V3FTT…
RT @NEJM: This week’s most cited articles: 1. Bempedoic Acid and Cardiovascular Outcomes in Statin-Intolerant Patients https://t.co/V3FTT…
RT @NEJM: This week’s most cited articles: 1. Bempedoic Acid and Cardiovascular Outcomes in Statin-Intolerant Patients https://t.co/V3FTT…
RT @NEJM: This week’s most cited articles: 1. Bempedoic Acid and Cardiovascular Outcomes in Statin-Intolerant Patients https://t.co/V3FTT…
RT @NEJM: This week’s most cited articles: 1. Bempedoic Acid and Cardiovascular Outcomes in Statin-Intolerant Patients https://t.co/V3FTT…
RT @NEJM: This week’s most cited articles: 1. Bempedoic Acid and Cardiovascular Outcomes in Statin-Intolerant Patients https://t.co/V3FTT…
RT @NEJM: This week’s most cited articles: 1. Bempedoic Acid and Cardiovascular Outcomes in Statin-Intolerant Patients https://t.co/V3FTT…
RT @NEJM: This week’s most cited articles: 1. Bempedoic Acid and Cardiovascular Outcomes in Statin-Intolerant Patients https://t.co/V3FTT…
RT @NEJM: This week’s most cited articles: 1. Bempedoic Acid and Cardiovascular Outcomes in Statin-Intolerant Patients https://t.co/V3FTT…
RT @NEJM: This week’s most cited articles: 1. Bempedoic Acid and Cardiovascular Outcomes in Statin-Intolerant Patients https://t.co/V3FTT…
RT @NEJM: This week’s most cited articles: 1. Bempedoic Acid and Cardiovascular Outcomes in Statin-Intolerant Patients https://t.co/V3FTT…
@RZhou15 Thank you for catching that. Here is the correct link: https://t.co/2GIT1lIxCb
RT @NEJM: This week’s most cited articles: 1. Bempedoic Acid and Cardiovascular Outcomes in Statin-Intolerant Patients https://t.co/V3FTT…
RT @NEJM: This week’s most cited articles: 1. Bempedoic Acid and Cardiovascular Outcomes in Statin-Intolerant Patients https://t.co/V3FTT…
RT @NEJM: This week’s most cited articles: 1. Bempedoic Acid and Cardiovascular Outcomes in Statin-Intolerant Patients https://t.co/V3FTT…
RT @NEJM: This week’s most cited articles: 1. Bempedoic Acid and Cardiovascular Outcomes in Statin-Intolerant Patients https://t.co/V3FTT…
RT @NEJM: This week’s most cited articles: 1. Bempedoic Acid and Cardiovascular Outcomes in Statin-Intolerant Patients https://t.co/V3FTT…
RT @NEJM: This week’s most cited articles: 1. Bempedoic Acid and Cardiovascular Outcomes in Statin-Intolerant Patients https://t.co/V3FTT…
RT @NEJM: This week’s most cited articles: 1. Bempedoic Acid and Cardiovascular Outcomes in Statin-Intolerant Patients https://t.co/V3FTT…
RT @NEJM: This week’s most cited articles: 1. Bempedoic Acid and Cardiovascular Outcomes in Statin-Intolerant Patients https://t.co/V3FTT…
RT @NEJM: This week’s most cited articles: 1. Bempedoic Acid and Cardiovascular Outcomes in Statin-Intolerant Patients https://t.co/V3FTT…
RT @NEJM: This week’s most cited articles: 1. Bempedoic Acid and Cardiovascular Outcomes in Statin-Intolerant Patients https://t.co/V3FTT…
RT @NEJM: This week’s most cited articles: 1. Bempedoic Acid and Cardiovascular Outcomes in Statin-Intolerant Patients https://t.co/V3FTT…
RT @NEJM: This week’s most cited articles: 1. Bempedoic Acid and Cardiovascular Outcomes in Statin-Intolerant Patients https://t.co/V3FTT…
RT @NEJM: This week’s most cited articles: 1. Bempedoic Acid and Cardiovascular Outcomes in Statin-Intolerant Patients https://t.co/V3FTT…
RT @NEJM: This week’s most cited articles: 1. Bempedoic Acid and Cardiovascular Outcomes in Statin-Intolerant Patients https://t.co/V3FTT…
This week’s most cited articles: 1. Bempedoic Acid and Cardiovascular Outcomes in Statin-Intolerant Patients https://t.co/V3FTTsOLd1 #cardiology https://t.co/ArVJZVd3pN
Bempedoic Acid and Cardiovascular Outcomes in Statin-Intolerant Patients https://t.co/0PO0KDDH6s
https://t.co/auCm71Jbv8
RT @NEJM: 2. Bempedoic Acid and Cardiovascular Outcomes in Statin-Intolerant Patients https://t.co/2GIT1lJ5rJ #cardiology https://t.co/qWIM…
RT @NEJM: 2. Bempedoic Acid and Cardiovascular Outcomes in Statin-Intolerant Patients https://t.co/2GIT1lJ5rJ #cardiology https://t.co/qWIM…
RT @NEJM: 2. Bempedoic Acid and Cardiovascular Outcomes in Statin-Intolerant Patients https://t.co/2GIT1lJ5rJ #cardiology https://t.co/qWIM…
RT @NEJM: 2. Bempedoic Acid and Cardiovascular Outcomes in Statin-Intolerant Patients https://t.co/2GIT1lJ5rJ #cardiology https://t.co/qWIM…
RT @NEJM: 2. Bempedoic Acid and Cardiovascular Outcomes in Statin-Intolerant Patients https://t.co/2GIT1lJ5rJ #cardiology https://t.co/qWIM…
2. Bempedoic Acid and Cardiovascular Outcomes in Statin-Intolerant Patients https://t.co/2GIT1lJ5rJ #cardiology https://t.co/qWIMFWKaMn
RT @NEJM: 2. Bempedoic Acid and Cardiovascular Outcomes in Statin-Intolerant Patients https://t.co/2GIT1lJ5rJ #cardiology https://t.co/l5Q0…
RT @FtNegar:
14) The authors' conclusions from #CLEAR_Outcomes were as follows: See also @NEJM https://t.co/OG2ntak2Ce https://t.co/mp2rexm1bm
RT @NEJM: 2. Bempedoic Acid and Cardiovascular Outcomes in Statin-Intolerant Patients https://t.co/2GIT1lJ5rJ #cardiology https://t.co/l5Q0…
RT @NEJM: 2. Bempedoic Acid and Cardiovascular Outcomes in Statin-Intolerant Patients https://t.co/2GIT1lJ5rJ #cardiology https://t.co/l5Q0…
RT @NEJM: 2. Bempedoic Acid and Cardiovascular Outcomes in Statin-Intolerant Patients https://t.co/2GIT1lJ5rJ #cardiology https://t.co/l5Q0…
RT @NEJM: 2. Bempedoic Acid and Cardiovascular Outcomes in Statin-Intolerant Patients https://t.co/2GIT1lJ5rJ #cardiology https://t.co/l5Q0…
RT @NEJM: 2. Bempedoic Acid and Cardiovascular Outcomes in Statin-Intolerant Patients https://t.co/2GIT1lJ5rJ #cardiology https://t.co/l5Q0…
2. Bempedoic Acid and Cardiovascular Outcomes in Statin-Intolerant Patients https://t.co/2GIT1lJ5rJ #cardiology https://t.co/l5Q03CMDdZ
RT @DrRosanel: Presenting at @FloridaACC Bempedoic Acid and Cardiovascular Outcomes in Statin-Intolerant Patients By Sarah Rosanel, MD, FAC…
Bempedoic acid: an ATP citrate lyase inhibitor, reduces low-density lipoprotein (LDL) cholesterol levels and is associated with a low incidence of muscle-related adverse events; its effects on cardiovascular outcomes remain uncertain https://t.co/Nry5SDpvnG
@Drlipid @johns9986 @Garyr9912 Please explain Incidence of primary endpoint sig lower Bempedoic acid, as were incidences of composite of deaths from CV causes, non-fatal stroke, non-fatal MI… No significant effects fatal or non-fatal stroke, death from CV causes, death from any cause https://t.co/SZQjmWjyCT
Presenting at @FloridaACC Bempedoic Acid and Cardiovascular Outcomes in Statin-Intolerant Patients By Sarah Rosanel, MD, FACC Clinical Cardiologist and Assistant Professor of Medicine Memorial Physician Group @mhshospital @SteveOmmen @DavidSpragg @CarlosAlfonsoMD @dkenigsberg https://t.co/A9bQDeZlgS
RT @javier20ch: Ácido bempedoico y MACE en
@infosalut @HManacor https://t.co/fglb7BAyMo
Bempedoic acid in Statin Intolerant Patients Lowers The Risk Of Major Adverse Cardiovascular Events! https://t.co/CYYejxaCmC #UMassJournalClub #HappyLearning https://t.co/ApzG9eVp35
High impact: Bempedoic Acid and Cardiovascular Outcomes in Statin-Intolerant Patients https://t.co/9YPWe2xODk
@kevinnbass Bempedoic acid https://t.co/3zvDe3rBUz
@drjohnm @kaulcsmc @f2harrell This is a substudy of the full trial, reported here: https://t.co/I6YqO5rimc Forest plot (Fig S3) shows significant difference between groups. This papers expands on it. https://t.co/kzGS9EUFns
RT @cardiomet_CE: 5b) The main #CLEAR_Outcomes trial comprised 14,014 pts (70% sec prevention, 30% primary)randomized to #bempedoic acid or…
ネクストールって「次のクレストール」って想いを込めてるんやろか？ Bempedoic Acid and Cardiovascular Outcomes in Statin-Intolerant Patients | NEJM https://t.co/6ekzyuS9v5
5b) The main #CLEAR_Outcomes trial comprised 14,014 pts (70% sec prevention, 30% primary)randomized to #bempedoic acid or placebo. The study ➡️ a highly significant 13% ⬇️ in the primary endpoint of 4 point #MACE & 15% ⬇️ in 3 point MACE. https://t.co/USdISGoEZO https://t.co/6GvidSZqeL
RT @CardioNerdsJC: To get your juices flowing, please see this outstanding visual abstract crafted by star fellow @CaliRClark Below is the…
RT @cardiomet_CE: 12) The main #CLEAR_Outcomestrial comprised 14,014 pts (70% sec prevention, 30% primary randomized to #bempedoic acid or…
RT @cardiomet_CE: 12) The main #CLEAR_Outcomestrial comprised 14,014 pts (70% sec prevention, 30% primary randomized to #bempedoic acid or…
RT @cardiomet_CE: 16a) To refresh your memory, the eligibility criteria for the #CLEAR_Outcomes trial were as follows: (
RT @cardiomet_CE: 12) The main #CLEAR_Outcomestrial comprised 14,014 pts (70% sec prevention, 30% primary randomized to #bempedoic acid or…
16a) To refresh your memory, the eligibility criteria for the #CLEAR_Outcomes trial were as follows: (
12) The main #CLEAR_Outcomestrial comprised 14,014 pts (70% sec prevention, 30% primary randomized to #bempedoic acid or placebo. The study showed a highly significant 13% decrease in the primary endpoint of 4 point #MACE & 15% decrease in 3 point MACE. https://t.co/USdISGpcPm https://t.co/SXC9d9Q0RT
Popular this week: Bempedoic Acid and Cardiovascular Outcomes in Statin-Intolerant Patients https://t.co/9YPWe2xODk #FOAMed
RT @CFAndersenMD: 12/ If a shared decision to re-trial a lower dose statin is unsuccessful, you would next reach for ezetimibe or a PCSK-9…
RT @CFAndersenMD: 12/ If a shared decision to re-trial a lower dose statin is unsuccessful, you would next reach for ezetimibe or a PCSK-9…
12/ If a shared decision to re-trial a lower dose statin is unsuccessful, you would next reach for ezetimibe or a PCSK-9 inhibitor. After that, you may consider bempedoic acid. https://t.co/Mwg9jUFPV5 https://t.co/ANIt0n2ETD
CLEAR Outcomes trial: In Pts requiring primary or secondary CVD prevention and statin intolerant, bempedoic acid 180 mg/d ⬇️MACE vs. placebo (ARR 1.6% at 40.6 mo; mainly from ⬇️MI & revasc). ⬆️transaminitis, hyperuricemia & gout with bempadoic acid. https://t.co/jZ8TLUGJZQ https://t.co/uMeXsLz9YR
RT @MWeintraubMD: Bempedoic acid is yet another addition to our arsenal of LDL lowering therapies. It's helpful in statin-intolerant pati…
RT @MWeintraubMD: Bempedoic acid is yet another addition to our arsenal of LDL lowering therapies. It's helpful in statin-intolerant pati…
Bempedoic acid is yet another addition to our arsenal of LDL lowering therapies. It's helpful in statin-intolerant patients likely because its a prodrug only activated in the liver to lower muscle-related symptoms
RT @cardiomet_CE: 8) Briefly, in CLEAR Outcomes (70% secondary prevention and 30% primary prevention prevention) patients were randomized t…
8) Briefly, in CLEAR Outcomes (70% secondary prevention and 30% primary prevention prevention) patients were randomized to bempedoic acid or placebo. The study showed a 12% decrease in the primary endpoint of 4 point MACE & 13% decrease in 3 point MACE. https://t.co/USdISGoEZO https://t.co/RUfAvaP41K
RT @AkivaRosenzveig: 1/19
RT @AkivaRosenzveig: 1/19
RT @AkivaRosenzveig: 1/19
RT @AkivaRosenzveig: 1/19
RT @CardioNerdsJC: To get your juices flowing, please see this outstanding visual abstract crafted by star fellow @CaliRClark Below is the…
RT @CardioNerdsJC: To get your juices flowing, please see this outstanding visual abstract crafted by star fellow @CaliRClark Below is the…
RT @AkivaRosenzveig: 1/19
RT @AkivaRosenzveig: 16/19 Now let's look at Table 2 of CLEAR Outcomes: ▶️Once we fail to meet significance (fatal or non-fatal stroke), s…
RT @AkivaRosenzveig: 16/19 Now let's look at Table 2 of CLEAR Outcomes: ▶️Once we fail to meet significance (fatal or non-fatal stroke), s…
16/19 Now let's look at Table 2 of CLEAR Outcomes: ▶️Once we fail to meet significance (fatal or non-fatal stroke), subsequent endpoints are not tested ▶️Thus, the fixed sequence hierarchical procedure was used https://t.co/j6OxOWMYRq https://t.co/c0NpH93Zk1
RT @BertrandBio: Bempedoic Acid and Cardiovascular Outcomes in Statin-Intolerant Patients (CLEAR study)| NEJM $ESPR ttps://www.nejm.org/doi…
Trend up+11: Nissen SE, ..., Clear Outcomes Investigators (N Engl J Med) __Bempedoic Acid and Cardiovascular Outcomes in Statin-Intolerant Patients__ https://t.co/mwYnUH4u6P
Journal Club SID Un’arma in più contro il colesterolo - A cura di Raffaele Galiero https://t.co/AKN2GoWUA4 https://t.co/mgmYcAweqp
Don't miss these discussions! #CardsJC Access the papers through Read beforehand: TRILUMINATE: https://t.co/ic9TbzyBxV CLEAR: https://t.co/GyOt7rRLUV RAPID-HF: https://t.co/xfPc5OKYLb https://t.co/oCTAKdH7Qx
RT @AtheroJC: Bempedoic Acid and Cardiovascular Outcomes in Statin-Intolerant Patients. https://t.co/Qu2RJ0tXIu
Bempedoic Acid and Cardiovascular Outcomes in Statin-Intolerant Patients. https://t.co/Qu2RJ0tXIu
Bempedoic Acid and Cardiovascular Outcomes in Statin-Intolerant Patients | NEJM https://t.co/2Xjnket1oD
Bempedoic Acid and Cardiovascular Outcomes in Statin-Intolerant Patients | NEJM https://t.co/vhJ2WDzTpR
Bempedoic Acid and #Cardiovascular Outcomes in Statin-Intolerant Patients Click here: https://t.co/pEJ3s36XeJ
Reference (https://t.co/pJL0ltIWpY)
論文: Bempedoic Acid and Cardiovascular Outcomes in Statin-Intolerant Patients https://t.co/fBanHsDngu NEJMはコロナ関係の論文が無料で読めるのに慣れすぎてたけど、別にすべてオープンアクセスという訳ではないんだなぁ。でも、無料会員登録すれば月に2本までは無料で読めるので見れた。
RT @BertrandBio: Bempedoic Acid and Cardiovascular Outcomes in Statin-Intolerant Patients (CLEAR study)| NEJM $ESPR ttps://www.nejm.org/doi…
Bempedoic Acid and Cardiovascular Outcomes in Statin-Intolerant Patients | NEJM ➡️ Among statin-intolerant patients, treatment with bempedoic acid was associated with a lower risk of major adverse cardiovascular events. https://t.co/orTUAg0Y4k
RT @acorderofort: Bempedoic Acid and Cardiovascular Outcomes in Statin-Intolerant Patients The CLEAR-OUTCOMES trial published in @NEJM @…
RT @acorderofort: Bempedoic Acid and Cardiovascular Outcomes in Statin-Intolerant Patients The CLEAR-OUTCOMES trial published in @NEJM @…
RT @acorderofort: Bempedoic Acid and Cardiovascular Outcomes in Statin-Intolerant Patients The CLEAR-OUTCOMES trial published in @NEJM @…
@DanClintonRN @stathitriadis @raphaels7 are you talking about https://t.co/qpXt2AuAAq ?
@dylanarmbruste3 @DanClintonRN @juanbadimon @secardiologia @lipidmir @ResiSec @Capijorge1 @JJheart_doc @acorderofort @lipiddoc @Drlipid @leopisla @Guio1212 @ValleAlfonso @JTLLERGO @SeguraCardio https://t.co/4qxd07Wozk here is the link.. But you have to signup..to full acces..sign up is free
@dylanarmbruste3 @DanClintonRN @juanbadimon @secardiologia @lipidmir @ResiSec @Capijorge1 @JJheart_doc @acorderofort @lipiddoc @Drlipid @leopisla @Guio1212 @ValleAlfonso @JTLLERGO @SeguraCardio https://t.co/4qxd07Wozk access is free but you have to sign up in that journal
RT @RevistaMFSamfyc: Ácido bempedoico y resultados cardiovasculares en pacientes con intolerancia a las estatinas https://t.co/VnxgvMy9m6 P…
Ácido bempedoico y resultados cardiovasculares en pacientes con intolerancia a las estatinas https://t.co/VnxgvMy9m6 PMID 36876740
RT @medical_xpress: Can't take #statins? New pill cuts #cholesterol, heart attacks @nejm https://t.co/je56rXLAhn https://t.co/mb6px7czNf
【RCT】許容できない有害事象によりスタチンを服用できない、服用が不本意な心血管疾患患者またはハイリスク患者へのベンペド酸投与は、プラセボ投与と比較して、MACEリスクを減少させた。 #ペ読 https://t.co/jR77hVYznW
RT @J_Circ_Assoc: #ACC / #NEJM 同時発表の論文二つ目は、スタチンが飲めないCVDハイリスク患者に朗報。 HMG-CoAのさらに上流を阻害してLDLを低下させるというベンペド酸が、主要心血管イベント発生を抑制しました。 https://t.co/…
RT @J_Circ_Assoc: #ACC / #NEJM 同時発表の論文二つ目は、スタチンが飲めないCVDハイリスク患者に朗報。 HMG-CoAのさらに上流を阻害してLDLを低下させるというベンペド酸が、主要心血管イベント発生を抑制しました。 https://t.co/…
RT @J_Circ_Assoc: #ACC / #NEJM 同時発表の論文二つ目は、スタチンが飲めないCVDハイリスク患者に朗報。 HMG-CoAのさらに上流を阻害してLDLを低下させるというベンペド酸が、主要心血管イベント発生を抑制しました。 https://t.co/…
Bempedoic acid ⬇️ LDL cholesterol and CRP and ⬇️ the risk of major adverse cardiovascular events in patients unable or unwilling to take statins. #MedTwitter #cholesterol #cardiology @NEJM https://t.co/FpzSaV3VxM https://t.co/oPCxMFQVRx
RT @J_Circ_Assoc: #ACC / #NEJM 同時発表の論文二つ目は、スタチンが飲めないCVDハイリスク患者に朗報。 HMG-CoAのさらに上流を阻害してLDLを低下させるというベンペド酸が、主要心血管イベント発生を抑制しました。 https://t.co/…
RT @J_Circ_Assoc: #ACC / #NEJM 同時発表の論文二つ目は、スタチンが飲めないCVDハイリスク患者に朗報。 HMG-CoAのさらに上流を阻害してLDLを低下させるというベンペド酸が、主要心血管イベント発生を抑制しました。 https://t.co/…
RT @J_Circ_Assoc: #ACC / #NEJM 同時発表の論文二つ目は、スタチンが飲めないCVDハイリスク患者に朗報。 HMG-CoAのさらに上流を阻害してLDLを低下させるというベンペド酸が、主要心血管イベント発生を抑制しました。 https://t.co/…
RT @J_Circ_Assoc: #ACC / #NEJM 同時発表の論文二つ目は、スタチンが飲めないCVDハイリスク患者に朗報。 HMG-CoAのさらに上流を阻害してLDLを低下させるというベンペド酸が、主要心血管イベント発生を抑制しました。 https://t.co/…
RT @medical_xpress: Can't take #statins? New pill cuts #cholesterol, heart attacks @nejm https://t.co/je56rXLAhn https://t.co/mb6px7czNf
RT @J_Circ_Assoc: #ACC / #NEJM 同時発表の論文二つ目は、スタチンが飲めないCVDハイリスク患者に朗報。 HMG-CoAのさらに上流を阻害してLDLを低下させるというベンペド酸が、主要心血管イベント発生を抑制しました。 https://t.co/…
RT @J_Circ_Assoc: #ACC / #NEJM 同時発表の論文二つ目は、スタチンが飲めないCVDハイリスク患者に朗報。 HMG-CoAのさらに上流を阻害してLDLを低下させるというベンペド酸が、主要心血管イベント発生を抑制しました。 https://t.co/…
RT @J_Circ_Assoc: #ACC / #NEJM 同時発表の論文二つ目は、スタチンが飲めないCVDハイリスク患者に朗報。 HMG-CoAのさらに上流を阻害してLDLを低下させるというベンペド酸が、主要心血管イベント発生を抑制しました。 https://t.co/…
RT @J_Circ_Assoc: #ACC / #NEJM 同時発表の論文二つ目は、スタチンが飲めないCVDハイリスク患者に朗報。 HMG-CoAのさらに上流を阻害してLDLを低下させるというベンペド酸が、主要心血管イベント発生を抑制しました。 https://t.co/…
#ACC / #NEJM 同時発表の論文二つ目は、スタチンが飲めないCVDハイリスク患者に朗報。 HMG-CoAのさらに上流を阻害してLDLを低下させるというベンペド酸が、主要心血管イベント発生を抑制しました。 https://t.co/wHDoFSqVqD ・2020年の大塚製薬リリースはこちら↓ https://t.co/wmyKotU8LU https://t.co/0ehMr4LZZl
Bempedoic Acid and Cardiovascular Outcomes in Statin-Intolerant Patients https://t.co/mztN1T37jE https://t.co/VwPKfOqRIU
Good News. Bempedoic Acid and Cardiovascular Outcomes in Statin-Intolerant Patients | NEJM https://t.co/T8VQb6BHjH
RT @medical_xpress: Can't take #statins? New pill cuts #cholesterol, heart attacks @nejm https://t.co/je56rXLAhn https://t.co/mb6px7czNf
Bempedoic Acid and Cardiovascular Outcomes in Statin-Intolerant Patients | NEJM https://t.co/57F6lXHVoL https://t.co/iqaEBSLgWG
RT @medical_xpress: Can't take #statins? New pill cuts #cholesterol, heart attacks @nejm https://t.co/je56rXLAhn https://t.co/mb6px7czNf
RT @medical_xpress: Can't take #statins? New pill cuts #cholesterol, heart attacks @nejm https://t.co/je56rXLAhn https://t.co/mb6px7czNf
Can't take #statins? New pill cuts #cholesterol, heart attacks @nejm https://t.co/je56rXLAhn https://t.co/mb6px7czNf
https://www.nejm.org/doi/full/10.1056/NEJMoa2215024